Isbn: 9783319795928 - lung cancer and personalized medicine: current knowledge and therapies (advances in experimental medicine and biology, band 893) (6 Ergebnisse)

Zustand: New. In.

Zustand: New.

Paperback. Zustand: Brand New. reprint edition. 244 pages. 9.25x6.10x0.58 inches. In Stock.

Taschenbuch. Zustand: Neu. Lung Cancer and Personalized Medicine | Current Knowledge and Therapies | Aamir Ahmad (u. a.) | Taschenbuch | Advances in Experimental Medicine and Biology | xiii | Englisch | 2019 | Springer | EAN 9783319795928 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer-statistics and epidemiology of lung cancer-along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer-immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.…

Zustand: Hervorragend. Zustand: Hervorragend | Sprache: Englisch | Produktart: Bücher | This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer¿statistics and epidemiology of lung cancer¿along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer¿immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.…